Important Update for Sage Therapeutics Investors
NEW YORK — Attorney advertising news brings important information for investors of Sage Therapeutics, Inc. (SAGE). Recently, a class action lawsuit has been initiated against the company and certain company officials. This lawsuit is designed specifically for those who have encountered significant financial losses due to misleading information regarding Sage's business practices and drug efficacy.
Details of the Class Action Lawsuit
The class action complaint alleges that during a specific period, leading up to mid-2024, Sage Therapeutics provided investors with false and misleading statements related to their drug developments. This misrepresentation has sparked considerable concern among shareholders, particularly those who invested in the company based on these assertions.
Key Allegations Against the Company
According to the complaint, several key claims have been made regarding the effectiveness of Sage's drugs, including zuranolone and SAGE-718. Investors were allegedly misled about these treatments' effectiveness in managing health conditions like major depressive disorder (MDD) and mild cognitive impairment (MCI) associated with Parkinson's disease (PD). Furthermore, it was stated that the U.S. FDA was unlikely to approve the new drug application for zuranolone in its current form.
The Fallout from Misleading Statements
As a result of these alleged misrepresentations, the lawsuit advocates for recovery of damages for shareholders who may have relied on Sage's public statements. The claims detail how the company overestimated the clinical, regulatory, and commercial prospects of their products, leading to significant stock depreciation.
How Can Affected Investors Participate?
The class action lawsuit is open to investors who acquired Sage securities during the defined period. Those affected are encouraged to visit the law firm’s website to learn more about how to get involved. Obtaining a copy of the complaint could be essential for understanding the lawsuit fully.
No Financial Risk to Join
It's worth noting that the law firm, Bronstein, Gewirtz & Grossman, operates on a contingency fee basis, meaning that shareholders do not incur any upfront costs to join this class action. Reimbursements for legal fees will come from any recovered funds following a successful outcome.
Expertise You Can Trust
Bronstein, Gewirtz & Grossman, LLC, carries a strong reputation for representing investors in securities fraud cases. They have garnered notable success in recovering substantial sums for those harmed by misleading corporate actions.
Contact Information
For those interested in joining or seeking more information about the class action lawsuit, please contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
Frequently Asked Questions
What is the purpose of the class action lawsuit against Sage Therapeutics?
The lawsuit aims to seek damages for investors misled by the company's false and misleading statements regarding its drug efficacy and business operations.
Who is eligible to participate in the class action?
Investors who purchased or acquired Sage Therapeutics securities between April 12, 2021, and July 23, 2024, may be eligible to participate.
What does it cost to join the lawsuit?
There are no costs to join the class action lawsuit as it operates on a contingency fee basis.
How can I get a copy of the complaint?
You can obtain a copy of the complaint by visiting the law firm's website that is handling the class action.
Why should I trust Bronstein, Gewirtz & Grossman?
Bronstein, Gewirtz & Grossman is nationally recognized for successfully representing investors in securities fraud cases and has recovered significant funds for clients.
